BPC January 29 update

Voyager VYGR shares surge 38% - partnership with ​Neurocrine Biosciences NBIX

Price and Volume Movers

Voyager Therapeutics, Inc. (NASDAQ: VYGR) and Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced a collaboration focused on the development of Voyager's gene therapy programs, VY-AADC for Parkinson's disease and VY-FXN01 for Friedreich's ataxia, as well as rights to two programs to be determined. Under the terms of the agreement, Neurocrine Biosciences has agreed to pay Voyager $165m in cash including a $115m upfront payment and a $50m equity investment at a share price of $11.96. In addition, Voyager may be entitled to earn up to $1.7b in milestone payments. Shares of Voyager closed up 38% to $11.12.

Allergan Plc (NYSE: AGN) shares closed down 9% to $145.12 following the release of 4Q earnings. The company forecast that 2019 revenue will below investor expectations and also noted that it no longer plans to sell its women’s health business. Forecast revenue of $15b-$15.3b is expected for 2019. Analysts had expected around $15.4b. It also noted that revenue from Restasis, its key revenue generator behind Botox, will decrease once it faces generic competition.

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced that their Phase 3 trial evaluating tanezumab 2.5 mg or 5 mg in patients with moderate-to-severe osteoarthritis (OA) pain, met all three co-primary endpoints at 24 weeks, demonstrating a statistically significant improvement in pain, physical function and the patients’ overall assessment of their OA compared to those receiving placebo.

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) shares closed down 14% to $18.58 on the back of a public offering announced after hours Monday of 8m common shares.


Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume


BioTime, Inc. (BTX): $1.39; +55%.

Zynerba Pharmaceuticals, Inc. (ZYNE): $4.81; +25%.

Conatus Pharmaceuticals Inc. (CNAT): $2.15; +23%.

Avadel Pharmaceuticals plc (AVDL): $2.70; +19%.

Jounce Therapeutics, Inc. (JNCE): $3.77; +10%.


Denali Therapeutics Inc. (DNLI): $18.82; -12%.

Leap Therapeutics, Inc. (LPTX): $2.52; -9%.

Intra-Cellular Therapies, Inc. (ITCI): $10.90; -8%.

Allakos Inc. (ALLK): $39.55; -8%.

Rocket Pharmaceuticals, Inc. (RCKT): $13.45; -8%.


Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

AGN – Allergan plc
Cenicriviroc (CVC)
Nonalcoholic steatohepatitis (NASH)

Phase 3 Phase 3 data due 2020.
$54.4 billion

AGN – Allergan plc
Chronic migraine

Phase 3 Phase 3 data due in 2020.
$54.4 billion

AGN – Allergan plc
ABP 798
RITUXAN biosimilar - non-Hodgkin lymphoma

Phase 3 Phase 3 data released January 24, 2019 - primary endpoint met.
$54.4 billion

AGN – Allergan plc
Bipolar I Depression

PDUFA FDA Approval announced May 28, 2019.
$54.4 billion

AGN – Allergan plc
Ulcerative colitis

Phase 2/3 Phase 2/3 data due 2020.
$54.4 billion

ALDX – Aldeyra Therapeutics Inc.
Proliferative vitreoretinopathy (PVR)

Phase 3 Phase 3 trial to be initiated 2H 2019 with initial data due 2020.
$156.1 million

ALLK – Allakos Inc.
Chronic Urticaria

Phase 2 Phase 2 additional data released February 11, 2019. 9% UAS7 complete responder rate.
$1.6 billion

AMGN – Amgen Inc.
Multiple Myeloma

Phase 3 Phase 3 data due 2019.
$107.4 billion

BIIB – Biogen Inc.
BIIB074 (Nav1.7 inhibitor)
Trigeminal Neuralgia

Phase 3 Phase 3 trial to be initiated later in 2019.
$45.3 billion

BIIB – Biogen Inc.
Cognitive Impairment Associated With Schizophrenia (CIAS)

Phase 2b Phase 2b data due late-2020.
$45.3 billion

CLRB – Cellectar Biosciences Inc.
CLR 131
Various lymphoma

Phase 2 Phase 2 top-line data due 2H 2019.
$20.1 million

MNLO – Menlo Therapeutics Inc.
Pruritus associated with psoriasis

Phase 2 Phase 3 planned for 2019.
$119.4 million

MNTA – Momenta Pharmaceuticals Inc.
Immune Thrombocytopenic Purpura (ITP)

Phase 1/2 Phase 1/2 dosing has commenced - noted January 29, 2019. Initial data due 1H 2020.
$1.1 billion

PFE – Pfizer Inc.
PF-04965842 - abrocitinib
Moderate-to-severe atopic dermatitis (AD)

Phase 3 Phase 3 data released May 15, 2019 met primary endpoints.
$237.7 billion